Goldstein, E. J. C.

Mayo Clinic

R. M. Alden Research Laboratory, Santa Monica, California, USA

U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016

Thorpe, Cheleste M. , McDermott, L. A., Tran, Midori , Chang, Justin , Jenkins, Stephen G., Patel, Robin , Forbes, Betty A., Johnson, Stuart , Gerding, Dale N. , Patel, Robin , Snydman, D R , Goldstein, E. J. C. , Snydman, David R.

Antimicrobial Agents and Chemotherapy | May 10, 2019 | Volume: 63 | Issue: 7 | Pages: No page available

In 2011, we initiated a sentinel surveillance network to assess changes in Clostridioides (formerly Clostridium ) difficile antimicrobial susceptibility to fidaxomicin from 6 geographically dispersed medical centers in the United States. This report summarizes data from 2013 to 2016. C. difficile isolates or toxin-positive stools from patients were referred to a central laboratory. Antimicrobial susceptibility was determined by agar dilution. CLSI, EUCAST, or FDA breakpoints were used, where applicable.

Goldstein, E. J. C.

Citations 1

U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016

Thorpe, Cheleste M. , McDermott, L. A., Tran, Midori , Chang, Justin , Jenkins, Stephen G., Patel, Robin , Forbes, Betty A., Johnson, Stuart , Gerding, Dale N. , Patel, Robin , Snydman, D R , Goldstein, E. J. C. , Snydman, David R.